Innospec expects continued improvement in overall market conditions as the post-COVID-19 economic re-opening progresses. They are managing cost inflation through price action and collaboration with customers. In terms of capital allocation, they have begun to pull forward incremental organic growth capital expenditures to support existing demand in Performance Chemicals and have significant balance sheet capacity to pursue complementary acquisition opportunities for this business.